Tisdag 26 November | 07:35:13 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-13 07:30 Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2024-05-14 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-20 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2023-05-10 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Devyser Diagnostics utvecklar, tillverkar och säljer genetiska tester till laboratorier globalt. Produkterna används för DNA-tester inom onkologi, transplantation och ärftliga sjukdomar för att möjliggöra skräddarsydd cancerbehandling, diagnostik av ett stort antal genetiska sjukdomar och uppföljning av transplanterade patienter. Bolaget har sitt huvudkontor i Hägersten.
2024-10-29 09:30:00

Devyser has entered an agreement with Thermo Fisher Scientific to collaborate on obtaining U.S. Food and Drug Administration (FDA) approval for One Lambda™ Devyser Accept cfDNA, their cobranded NGS solution for detecting donor-derived cell-free DNA (ddcfDNA) in blood samples from kidney-transplanted patients. Once approved, this will be the first FDA-approved Devyser post-transplant monitoring product.

“Securing FDA-approval for One Lambda Devyser Accept cfDNA has the potential to change how kidney transplant monitoring is done in the United States. The collaboration with Thermo Fisher Scientific, the world leader in serving science, is a great opportunity for us to combine the strengths of both companies to fast-track studies and complete the necessary regulatory activities to obtain FDA approval in the shortest time possible.  With Thermo Fisher’s expertise and experience working with regulators, we are confident that this collaboration will secure the most efficient pathway for FDA-approval of our post-transplant product in the U.S.,” says Fredrik Alpsten, Devyser CEO.  
 
Thermo Fisher is the exclusive distributor of Devyser’s transplantation products globally. This includes One Lambda™ Devyser Accept cfDNA and One Lambda™ Devyser Chimerism for screening and follow-up of post stem cell transplantation, along with the corresponding software solutions. 
 
“We are pleased to further our collaboration with Devyser, with the ultimate aim of enabling our customers to enhance surveillance and improve quality of life for the more than 150,000 Americans living with a kidney transplant," says Tina Liedtky, President, Transplant Diagnostics, Thermo Fisher Scientific.  
 
One Lambda Devyser Accept cfDNA is CE-IVDR marked but not FDA-cleared. Availability in each country depends on local regulatory marketing authorization status. Please consult your local sales representative for details.